VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE AMEX: CVM) announced today it has received governmental approval from the Taiwanese Department of Health to begin enrollment of subjects for a Phase III clinical trial of Multikine® in Taiwan. Multikine is the Company’s flagship immunotherapy developed as a first-line standard of care in treating head and neck cancer. Taiwan is one of nine countries to participate in this global Phase III trial.
